Bio-Bridge Science Announces Allowance of All Claims of a Second U.S. Patent Application on the Papillomavirus Pseudovirus Techn

  
    
  
  
    
      Bio-Bridge Science, Inc.(OTCBB:BGES) a developer of vaccines with broad 
      preventative and therapeutic applications, is pleased to announce that 
      all the pending claims of a second patent application on the 
      papillomavirus pseudovirus technology have been allowed by the U.S. 
      Patent and Trademark Office. Bio-Bridge expects the second patent will 
      be issued upon payment of the issue fee. The first U.S. patent (number 
      6,878,541 B2) on the papillomavirus pseudovirus technology was issued in 
      2005. The second patent covers broader aspects of the invention and 
      further protects the intellectual property in the papillomavirus 
      pseudovirus technology. Loyola University Chicago owns the patent and 
      has exclusively licensed the technology to Bio-Bridge Science, Inc.
    
    
      About Bio-Bridge Science:
    
    
      Bio-Bridge Science (http://www.bio-bridge-science.com/) 
      is a biotechnology firm focused on the development of vaccines with 
      broad therapeutic and preventive applications. Bio-Bridge is developing 
      a promising new HIV Vaccine that is expected to enter clinical trials in 
      the near future in China. The vaccine, based on exclusive technology 
      co-developed by CEO Dr. Liang Qiao, an associate professor at Loyola 
      University Chicago's Strich School of Medicine, targets infection in 
      mucosal tissues, which is a unique approach to prevent and treat HIV 
      infection. Bio-Bridge Science's GMP facility will also be used to 
      develop vaccines against cervical cancer and colon cancer under the same 
      technology platform. The company plans to develop these vaccines in the 
      United States and Japan in the future.
    
    
      Forward Looking Statements:
    
    
      This press release contains forward-looking statements as defined by the 
      Private Securities Litigation Reform Act of 1995. Forward-looking 
      statements include statements concerning plans, objectives, goals, 
      strategies, future events or performance, and underlying assumptions and 
      other statements that are other than statements of historical facts. 
      These statements are subject to uncertainties and risks including, but 
      not limited to, product and service demand and acceptance, changes in 
      technology, economic conditions, the impact of competition and pricing, 
      government regulation, and other risks defined in this document and in 
      statements filed from time to time with the Securities and Exchange 
      Commission. All such forward-looking statements, whether written or 
      oral, and whether made by or on behalf of the company, are expressly 
      qualified by these cautionary statements and any other cautionary 
      statements which may accompany the forward-looking statements. In 
      addition, the company disclaims any obligation to update any 
      forward-looking statements to reflect events or circumstances after the 
      date hereof. Please refer to SEC filings for additional information.
    
  
Bio-Bridge Science, Inc.(OTCBB:BGES) a developer of vaccines with
broad preventative and therapeutic applications, is pleased to
announce that all the pending claims of a second patent application on
the papillomavirus pseudovirus technology have been allowed by the
U.S. Patent and Trademark Office. Bio-Bridge expects the second patent
will be issued upon payment of the issue fee. The first U.S. patent
(number 6,878,541 B2) on the papillomavirus pseudovirus technology was
issued in 2005. The second patent covers broader aspects of the
invention and further protects the intellectual property in the
papillomavirus pseudovirus technology. Loyola University Chicago owns
the patent and has exclusively licensed the technology to Bio-Bridge
Science, Inc.

   About Bio-Bridge Science:

   Bio-Bridge Science (http://www.bio-bridge-science.com/) is a
biotechnology firm focused on the development of vaccines with broad
therapeutic and preventive applications. Bio-Bridge is developing a
promising new HIV Vaccine that is expected to enter clinical trials in
the near future in China. The vaccine, based on exclusive technology
co-developed by CEO Dr. Liang Qiao, an associate professor at Loyola
University Chicago's Strich School of Medicine, targets infection in
mucosal tissues, which is a unique approach to prevent and treat HIV
infection. Bio-Bridge Science's GMP facility will also be used to
develop vaccines against cervical cancer and colon cancer under the
same technology platform. The company plans to develop these vaccines
in the United States and Japan in the future.

   Forward Looking Statements:

   This press release contains forward-looking statements as defined
by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. These statements are subject to
uncertainties and risks including, but not limited to, product and
service demand and acceptance, changes in technology, economic
conditions, the impact of competition and pricing, government
regulation, and other risks defined in this document and in statements
filed from time to time with the Securities and Exchange Commission.
All such forward-looking statements, whether written or oral, and
whether made by or on behalf of the company, are expressly qualified
by these cautionary statements and any other cautionary statements
which may accompany the forward-looking statements. In addition, the
company disclaims any obligation to update any forward-looking
statements to reflect events or circumstances after the date hereof.
Please refer to SEC filings for additional information.